golcadomide (CC-99282) / BMS - LARVOL DELTA

Golcadomide: “Golcadomide + R-CHOP in 1L LBCL led to high CMR rates and encouraging 2-year PFS rate of 79%” Large B-cell lymphoma (Bristol-Myers Squibb) - Virtual Investor Presentation on Hematology Programs: “Golcadomide + R-CHOP demonstrated a predictable and manageable safety profile”

P1 data • Hematological Malignancies • Large B Cell Lymphoma • Oncology

Golcadomide demonstrates potent antiproliferative activity in T-cell lymphoma via degradation of IKZF1 and IKZF3 (ASH 2025) - "Overexpression of thesemutants effectively protected the cells from golcadomide-induced antiproliferation in all tested modelsand also conferred resistance against lenalidomide in lenalidomide-sensitive cell lines.In summary, these findings support the continued development of golcadomide as a promisingtherapeutic for T-cell lymphomas. Its potent efficacy across multiple TCL subtypes and mechanismsinvolving IKZF1 and IKZF3 degradation highlight a novel strategy to address unmet clinical need in thischallenging disease."

Adult T-Cell Leukemia-Lymphoma • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CRBN • IKZF1 • IKZF3

IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment (ASH 2025) - "Introduction: Cereblon E3 ligase modulating drugs (CELMoDs) represent a novel class ofimmunomodulatory agents that target IKZF1 and IKZF3 for degradation, building upon earliergenerations such as Thalidomide and Avadomide...Similarfindings were observed in patients treated with Golcadomide (Golca), a next generation CELMoDcurrently under clinical investigation for DLBCL, follicular lymphoma, and T cell lymphoma, and wererecapitulated in a genetically engineered humanized cereblon-DLBCL mouse model, highlighting thetranslational significance of CELMoD-induced immune modulation... This study uncovers a novel mechanism by which Golca binding to CRBN mediates enhancedubiquitination of three specific lysine residues on IQGAP1. This modification increased IQGAP1'sinteraction with Rac, CDC42 and actin, thereby promoting directional immune cell migration. Ourfindings provide the first description of IQGAP1 as a non-degraded CELMoD substrate, directly linking itsbiological..."

Biomarker • Immune cell • Tumor microenvironment • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CDC42 • CRBN • IKZF1 • IKZF3 • IQGAP1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2, P3 | "Median number of prior treatments was 4.5 (range, 2–6) in Part A and 3 (range, 1–12)in Part B Cohort D. Approximately one-third of the treated patients were exposed to prior T-cell–redirecting therapy, approximately one-third had prior lenalidomide (len) exposure, and approximatelyone-third were refractory to the last regimen received. A higher ORR/CRR and similar tolerability were observed with GOLCA 0.4 mg + R vsGOLCA 0.2 mg + R, including in patients with prior len-based and/or T-cell–redirecting treatment. Thesedata support continued development of GOLCA 0.4 mg + R as a fixed-duration, chemotherapy-free,outpatient option in the ongoing Phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Cardiovascular • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Lymphoma • Neutropenia • Pulmonary Embolism • Respiratory Diseases • CRBN • IKZF1

Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international prognostic index: A real-world analysis from the danish lymphoma registry (ASH 2025) - P3 | "This study aimed to present real-world outcomes among patients treated with R-CHOP/R-CHOP-like (+/-etoposide) regimens who met the inclusion criteria for four currently ongoing phase 3 trials: GOLSEEK-1(NCT06356129, R-CHOP+golcadomide vs. R-CHOP+placebo), SKYGLO (NCT06047080,glofitamab+polatuzumab+R-CHP vs. polatuzumab-R-CHP), ENGINE-1 (NCT03263026, enzastaurine+R-CHOP vs. R-CHOP), and ZUMA-23 (NCT05605899, axi-cel vs. standard of care 1st line therapy). This retrospective analysis of 3,475 newly diagnosed DLBCL patients assessed real-worldoutcomes and the impact of trial eligibility criteria across four ongoing frontline trials. Variations in IPIthresholds and clinical/laboratory requirements resulted in substantial differences in the proportion oftrial-eligible patients. Among the analyzed trials, ZUMA-23 had the most stringent eligibility criteria,resulting in the lowest eligibility rate and the exclusion of many younger individuals."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma (ASH 2025) - P3 | "Rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisone (R-CHOP) is the standard first-line treatment for DLBCL, achieving cure rates inapproximately 60–70% of patients...GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.In the Phase 1b study CC-220-DLBCL-001, GOLCA in combination with R-CHOP demonstrated apredictable and manageable safety profile with high rates of durable responses, irrespective of COO, inpreviously untreated aggressive B-cell lymphomas (BCL), including promising activity in HR patients(Amzallag et al, ASH 2024, #579)...After a screening period of ≤4 weeks, patients will receive either GOLCA (0.4 mg) or placebo orallyonce daily for 7 consecutive days in each of 6 cycles, combined with R-CHOP every 21 days.The primary endpoint is progression-free survival (PFS) by investigator..."

Clinical • P3 data • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Follicular Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • ALK • BCL2 • CRBN • IKZF1

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas (ASH 2025) - P1/2 | "Each sub-study has additional and specific inclusion and exclusion criteria.Sub-Studies: Two sub-studies are currently open:GolcAza: evaluates the combination of golcadomide and oral azacitidine in R/R follicular helper T-celllymphoma. PlaTform represents a novel academic initiative dedicated to R/R PTCL, designed toaccelerate therapeutic innovation in this underserved population.Acknowledgement: We wish to thank the patients and their families for their participation in the clinicaltrials, iOnctura for providing access to roginolisib, and Bristol-Myers Squibb for providing access togolcadomide and azacitidine."

Clinical • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • T-Cell Large Granular Lymphocyte Leukemia • PIK3CD

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy (ASH 2025) - P3 | "Patients randomized to IC will receive rituximab-lenalidomide (lenalidomide 20mg Days 1–21 every 28 days plus rituximab) for 5 cycles followed by lenalidomide monotherapy for 7cycles (total of 12 cycles) or rituximab-chemotherapy (R-CHOP or R-Bendamustine) for 6 cycles.Randomization will be stratified by progression of disease within 24 months vs >24 months from initialtherapy, number of prior systemic regimens (2L vs 3L+), and comparator IC regimen. Patients will be followed for up to five years from the last patient's first visit.GOLSEEK-4 will evaluate the safety and efficacy of golcadomide + rituximab as a fixed-duration,chemotherapy-free, outpatient treatment for patients with R/R FL, who have received ≥1 line of systemictherapy as compared to Investigator's choice of R-chemo or R-len. Recruitment started July 2025.AcknowledgementBMS Artificial Intelligence was used to revise existing text with human author oversight."

Clinical • P3 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2 | "GOLCA+ R induced a decrease in circulating tumor DNA across tumor variants. These data support the ongoingdevelopment of GOLCA + R in patients with R/R non-Hodgkin lymphoma."

Clinical • P1/2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results (ASH 2025) - P1, P3 | "GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.CC-220-DLBCL-001 (NCT04884035) is an ongoing Phase 1b, open-label, multicenter trial to assess safetyand preliminary efficacy of GOLCA+R-CHOP in previously untreated a-BCL. GOLCA+R-CHOP demonstrated a predictable and manageablesafety profile with low rates of non-hematologic AEs; addition of GOLCA to R-CHOP did not compromiseSOC delivery. These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129)."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastrointestinal Disorder • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CRBN • IKZF1

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (ASH 2025) - P1 | "In Arm 2, ptsreceived intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg),then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1–10; 21-daycycles) in dose escalation (0.2 or 0.4mg). Early data suggest Mosun/Glofit+Golca is an active regimen with a manageable safetyprofile consistent with the risks of individual agents. No new safety signals were observed; CRS eventswere low grade. Neutropenia was the most common overlapping toxicity and was manageable withprophylactic and therapeutic G-CSF."

Clinical • Combination therapy • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Cognitive Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Varicella Zoster • CRBN • IKZF1

Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting (PRNewswire)

Clinical data • Diagnostic • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Large B Cell Lymphoma • Marginal Zone Lymphoma

Extended follow-up of golcadomide plus rituximab in patients with relapsed or refractory follicular lymphoma (Abstract #1006) and relapsed or refractory diffuse large B-cell lymphoma (Abstract #479) (Businesswire) - "Bristol Myers Squibb...reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting....Golcadomide plus rituximab continued to show promising efficacy and durable responses in heavily pre-treated patients with relapsed or refractory follicular lymphoma (R/R FL) and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)....In FL, golcadomide 0.4 mg plus rituximab showed an overall response rate (ORR) of 97% and a complete response rate (CRR) of 78%. In DLBCL, golcadomide 0.4 mg plus rituximab showed an ORR of 58% and a CRR of 44%."

P1/2 data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma

Two-year follow-up of golcadomide plus R-CHOP in patients with previously untreated aggressive B-cell lymphoma (Abstract #476) (Businesswire) - "Bristol Myers Squibb...reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting....At median follow-up of 24 months, golcadomide 0.4 mg plus R-CHOP continued to demonstrate deep, durable responses and promising progression-free survival (PFS). PFS rate of 79% across overall and high-risk populations. Complete metabolic response rate (CMR) was 88% and minimal residual disease (MRD) negativity rate was 90%, irrespective of cell of origin. In high-risk patients, CMR was 89% and MRD negativity was 93%."

P1 data • B Cell Lymphoma

Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Seoul National University Hospital

New P1/2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio (Businesswire) - "Data from the company’s targeted protein degradation and cell therapy research platforms, as well as other hematology programs, will highlight development across key disease areas including multiple myeloma, lymphomas and myeloid diseases."

Clinical data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Large B Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL (ASH 2023) - P1/2 | "Similar synergistic effects were found when combining GOLCA with JQ1, another tool compound BET inhibitor, confirming BET inhibition potentiates the anti-DLBCL effects of the CELMoD agent. BET inhibition potentiates anti-proliferative effects of GOLCA in DLBCL cells through synergistic induction of p21 and inhibition of E2F signaling. The synergetic effects of BMS-986158 and GOLCA suggest potential clinical benefits of combining lower doses of single agents to achieve better efficacy with reduced risk of adverse effects."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • AURKA • BRD4 • CDC45 • CDKN1A • CHEK1 • CRBN • E2F1 • IKZF1 • IL17RB • SKP2

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (ASH 2023) - P1/2 | "Golcadomide oral therapy combined with rituximab showed promising efficacy in heavily pretreated patients with R/R DLBCL, including 1 durable response over 300 days. Golcadomide can be safely combined with rituximab, and the combination showed a safety profile similar to that previously reported for golcadomide monotherapy."

Clinical • P1/2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion (ASH 2023) - P1 | "Introduction Up to 40% of pts with diffuse large B-cell lymphoma (DLBCL) relapse after first-line chemo-immunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...CC-220-DLBCL-001 (NCT04884035) is an ongoing open-label, multicenter, dose escalation and expansion trial to assess safety and preliminary efficacy of CELMoD agents + R-CHOP for untreated a-BCL...Efficacy results and substantial ctDNA decrease indicate robust clinical activity in frontline DLBCL, with a high CMR rate at EoT, particularly among patients treated at DL1. Study support Bristol Myers Squibb."

Clinical • P1 data • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Thrombocytopenia • Venous Thromboembolism • IKZF1

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study (ASH 2023) - P2 | "Survival probabilities will be reported using Kaplan-Meier analysis. Status: This trial received IRB approval on 14 July 2023 (HREC/88597/Austin-2023) at Austin Health, Heidelberg, Australia."

P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CRBN • IKZF1

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma (ASH 2023) - P1 | "In the ongoing CC-220-DLBCL-001 study (NCT04884035), GOLCA dose finding is underway in patients with previously untreated aggressive B-cell lymphoma (BCL), in combination with R-CHOP in 21-day (D) cycles (C), at a variety of GOLCA dose levels (DLs) and schedules: DL-1 = 0.2 mg D1-7, DL1 = 0.4 mg D1-7, and DL2 = 0.4 mg D1-10. Translational data demonstrate the potency of GOLCA and will support future frontline clinical trial designs in patients with untreated aggressive BCL. Study support: Celgene, a Bristol-Myers Squibb Company"

Biomarker • Circulating tumor DNA • Clinical • PK/PD data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1

Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma (ASH 2024) - P2 | "Given the promising results of administering lenalidomide post CAR-T, we hypothesized that golcadomide administration post CAR-T could further improve clinical results. Quantitative and qualitative analysis of Minimal Residual Disease by circulating tumor (Ct) DNA will also be assessed.The sponsor of the trial is the Lymphoma Academic Research Organisation (LYSARC) with the support of Bristol Myers Squibb. The first patient has been included on 25 June 2024."

Clinical • P2 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma (ASH 2024) - P2 | "R-lenalidomide (R-Len), a chemo-free alternative to R-based chemoimmunotherapy, has recently been listed as a chemo-free option in the National Comprehensive Cancer Network® (NCCN) guidelines...Study Design and Methods After a screening period of ≤ 5 weeks, approximately 90 pts with newly diagnosed advanced-stage FL will be randomized 1 : 1 : 1 between GOLCA plus rituximab at a dose of 0.2 mg or 0.4 mg once daily from day 1 to 14 every 28 days for 12 cycles or investigator's choice R-chemo (R-CHOP or R-bendamustine)...The primary endpoint is complete metabolic response (CMR) during the GOLCA plus rituximab combination treatment period, assessed by the investigator and based on Lugano 2014 Response Criteria. Secondary endpoints include progression-free survival, overall survival, overall response rate, duration of response, complete response rate at 30 months, CMR rate at 6 months and 12 months, and safety outcomes."

Clinical • Combination therapy • Metastases • P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1

Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3) (ASH 2024) - P1/2 | "It is much more efficient than lenalidomide at driving the closed, active conformation of cereblon which leads to increased potency (Chavez et al, EHA 2024). ORR in the ATL cohort is evaluated by assessment per international consensus response criteria for ATL with slight modifications; ORR in the PTCL cohort is evaluated by assessment per response criteria according to Lugano Classification (CT-based). Status The trial is ongoing, and patients will be recruited from 40 sites in Japan."

P1/2 data • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mental Retardation • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Psychiatry • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CRBN • IKZF1

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma (ASH 2024) - P3 | "Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), typically administered for 6 cycles, is the standard therapy for DLBCL and is curative in ~60–70% of patients (pts)...In the phase 1b study CC-220-DLBCL-001, GOLCA combined with R-CHOP was well tolerated, showing promising activity and combinability with high rates of durable responses irrespective of cell of origin in pts with previously untreated aggressive BCL, including those with HR disease (Hoffmann et al...Patient follow-up will occur for up to approximately 67 months after beginning treatment. This study is recruiting at 293 sites in 37 countries, across the United States, Europe, Latin America, and East Asia."

Clinical • P3 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Follicular Lymphoma • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • Targeted Protein Degradation • ALK • BCL2 • CRBN • IKZF1